REFERENCES
1. Ben-Ari Y, Cherubini E, Corradetti R, Gaiarsa JL. Giant synaptic potentials in immature rat CA3 hippocampal neurones. J Physiol 1989;416:303-25.
2. Ben-ari Y, Tseeb V, Raggozzino D, Khazipov R, Gaiarsa J. γ-Aminobutyric acid (GABA): a fast excitatory transmitter which may regulate the development of hippocampal neurones in early postnatal life. Prog Brain Res 1994;102:261-73.
3. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 2002;3:728-39.
4. Ben-Ari Y. The GABA excitatory/inhibitory developmental sequence: a personal journey. Neurosci 2014;279:187-219.
5. Yamada J, Okabe A, Toyoda H, Kilb W, Luhmann HJ, Fukuda A. Cl- uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1. J Physiol 2004;557:829-41.
6. Watanabe M, Fukuda A. Development and regulation of chloride homeostasis in the central nervous system. Front Cell Neurosci 2015;9:371.
7. Luhmann HJ, Kirischuk S, Sinning A, Kilb W. Early GABAergic circuitry in the cerebral cortex. Curr Opin Neurobiol 2014;26:72-8.
8. Chabrol FP, Eglen SJ, Sernagor E. GABAergic control of retinal ganglion cell dendritic development. Neurosci 2012;227:30-43.
9. Zhang RW, Wei HP, Xia YM, Du JL. Development of light response and GABAergic excitation-to-inhibition switch in zebrafish retinal ganglion cells. J Physiol 2010;588:2557-69.
10. Ben-Ari Y, Krnjević K, Reiffenstein RJ, Reinhardt W. Inhibitory conductance changes and action of gamma-aminobutyrate in rat hippocampus. Neurosci 1981;6:2445-63.
11. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 2007;87:1215-84.
12. Leinekugel X, Medina I, Khalilov I, Ben-Ari Y, Khazipov R. Ca2+ oscillations mediated by the synergistic excitatory actions of GABAA and NMDA receptors in the neonatal hippocampus. Neuron 1997;18:243-55.
13. Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL. GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois'. Trends Neurosci 1997;20:523-9.
14. Heck N, Kilb W, Reiprich P, et al. GABA-A receptors regulate neocortical neuronal migration in vitro and in vivo. Cereb Cortex 2007;17:138-48.
15. Inada H, Watanabe M, Uchida T, et al. GABA regulates the multidirectional tangential migration of GABAergic interneurons in living neonatal mice. PLoS One 2011;6:e27048.
16. Kirischuk S, Sinning A, Blanquie O, Yang JW, Luhmann HJ, Kilb W. Modulation of neocortical development by early neuronal activity: physiology and pathophysiology. Front Cell Neurosci 2017;11:379.
17. Griguoli M, Cherubini E. Early correlated network activity in the hippocampus: its putative role in shaping neuronal circuits. Front Cell Neurosci 2017;11:255.
18. Kasyanov AM, Safiulina VF, Voronin LL, Cherubini E. GABA-mediated giant depolarizing potentials as coincidence detectors for enhancing synaptic efficacy in the developing hippocampus. Proc Natl Acad Sci U S A 2004;101:3967-72.
19. Rivera C, Voipio J, Payne JA, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999;397:251-5.
20. Khalilov I, Chazal G, Chudotvorova I, et al. Enhanced synaptic activity and epileptiform events in the embryonic KCC2 deficient hippocampus. Front Cell Neurosci 2011;5:23.
21. Wang DD, Kriegstein AR. Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. Cereb Cortex 2011;21:574-87.
22. Zheng JJ, Lee S, Zhou ZJ. A developmental switch in the excitability and function of the starburst network in the mammalian retina. Neuron 2004;44:851-64.
23. Spitzer NC. Neurotransmitter switching in the developing and adult brain. Annu Rev Neurosci 2017;40:1-19.
24. Moody WJ, Bosma MM. Ion channel development, spontaneous activity, and activity-dependent development in nerve and muscle cells. Physiol Rev 2005;85:883-941.
25. Dehorter N, Vinay L, Hammond C, Ben-Ari Y. Timing of developmental sequences in different brain structures: physiological and pathological implications. Eur J Neurosci 2012;35:1846-56.
26. Ben-Ari Y. Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci 2008;31:626-36.
27. Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002;298:1418-21.
28. Ben-Ari Y. NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders. Trends Neurosci 2017;40:536-54.
29. Lozovaya N, Eftekhari S, Cloarec R, et al. GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. Nat Commun 2018;9:1422.
30. Thompson EG, Sontheimer H. A role for ion channels in perivascular glioma invasion. Eur Biophys J 2016;45:635-48.
31. Garzon-Muvdi T, Schiapparelli P, ap Rhys C, et al. Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. PLoS Biol 2012;10:e1001320.
32. Damier P, Hammond C, Ben-Ari Y. Bumetanide to treat parkinson disease: a report of 4 cases. Clin Neuropharmacol 2016;39:57-9.
33. Gagnon M, Bergeron MJ, Lavertu G, et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat Med 2013;19:1524-8.
34. Savardi A, Borgogno M, De Vivo M, Cancedda L. Pharmacological tools to target NKCC1 in brain disorders. Trends Pharmacol Sci 2021;42:1009-34.
35. Capsoni S, Arisi I, Malerba F, D'Onofrio M, Cattaneo A, Cherubini E. Targeting the cation-chloride co-transporter NKCC1 to re-establish GABAergic inhibition and an appropriate excitatory/inhibitory balance in selective neuronal circuits: a novel approach for the treatment of Alzheimer's disease. Brain Sci 2022;12:783.
36. Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. Clin Pharmacol Ther 1995;57:42-51.
37. Flamenbaum W, Friedman R. Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic. Pharmacotherapy 1982;2:213-22.
38. Pressler RM, Boylan GB, Marlow N, et al. NEonatal seizure treatment with Medication Off-patent (NEMO) consortium. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol 2015;14:469-77.
39. Ben-Ari Y, Delpire E. Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. Epilepsia 2021;62:935-40.
40. Löscher W, Kaila K. Reply to the commentary by Ben-Ari and delpire: bumetanide and neonatal seizures: fiction versus reality. Epilepsia 2021;62:941-6.
41. Delpire E, Ben-Ari Y. A wholistic view of how bumetanide attenuates autism spectrum disorders. Cells 2022;11:2419.
42. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202.
43. Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 2010;99:1885-8.
44. Lemonnier E, Villeneuve N, Sonie S, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl sych 2017;7:e1056.
45. Li Q, Zhang L, Shan H, et al. The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. Transl sych 2022;12:228.
46. Dai Y, Zhang L, Yu J, et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Sci Bull 2021;66:1591-8.
47. Fernell E, Gustafsson P, Gillberg C. Bumetanide for autism: open-label trial in six children. Acta Paediatr 2021;110:1548-53.
48. Du L, Shan L, Wang B, et al. A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism. J Child Adolesc Psychopharmacol 2015;25:585-8.
49. Shaker E, Agami OE, Salamah A. Bumetanide, a diuretic that can help children with autism spectrum disorder. CNS Neurol Disord Drug Targets 2023;23:536-42.
50. Sprengers JJ, van Andel DM, Zuithoff NPA, et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. J Am Acad Child Adolesc Psychiatry 2021;60:865-76.
51. van Andel DM, Sprengers JJ, Oranje B, Scheepers FE, Jansen FE, Bruining H. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. Mol Autism 2020;11:30.
52. Hadjikhani N, Zürcher NR, Rogier O, et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism 2015;19:149-57.
53. Hadjikhani N, Åsberg Johnels J, Zürcher NR, et al. Look me in the eyes: constraining gaze in the eye-region provokes abnormally high subcortical activation in autism. Sci Rep 2017;7:3163.
54. Hadjikhani N, Åsberg Johnels J, Lassalle A, et al. Bumetanide for autism: more eye contact, less amygdala activation. Sci Rep 2018;8:3602.
55. Crutel V, Lambert E, Penelaud PF, et al. Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: design of two phase III studies (SIGN Trials). J Autism Dev Disord 2021;51:2959-72.
56. Fuentes J, Parellada M, Georgoula C, et al. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase III studies. Autism Res 2023;16:2021-34.
57. Tobe R, Zhu Y, Gleissl T, et al. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder. Neuropsychopharmacol 2023;48:1201-16.
58. Juarez-Martinez EL, Sprengers JJ, Cristian G, et al. Prediction of behavioral improvement through resting-state electroencephalography and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder. Biol Psychiatry Cogn Neurosci Neuroimaging 2023;8:251-61.
